Aa
New treatments?
Hi all,
I was diagnosed with HCV nearly 4 years ago and 3 years ago underwent 72 weeks of interferon/ribavirin treatment. Prior to treatment I had stage 1 fibrosis and a second biopsy 18 months ago a second biopsy indicated stage 3. So 72 weeks of treatment, which failed and a deteriorating liver. My question is does anyone know of any new developments in treatment for GT 3a?
I was diagnosed with HCV nearly 4 years ago and 3 years ago underwent 72 weeks of interferon/ribavirin treatment. Prior to treatment I had stage 1 fibrosis and a second biopsy 18 months ago a second biopsy indicated stage 3. So 72 weeks of treatment, which failed and a deteriorating liver. My question is does anyone know of any new developments in treatment for GT 3a?
Thanks HectorSF,
So if I have read this correctly (laymans terms), for gen3 the results are good, better for 16 weeks than 12 weeks.
It also looks as though the side effects aren't as heavy as the Ribivin/Interferon (from which I had a large number)
I'm in the UK and whether NICE will approve the treatment or not is another matter.
To be honest this is the best news I've heard in a long time. There is light at the end of the tunnel.
So if I have read this correctly (laymans terms), for gen3 the results are good, better for 16 weeks than 12 weeks.
It also looks as though the side effects aren't as heavy as the Ribivin/Interferon (from which I had a large number)
I'm in the UK and whether NICE will approve the treatment or not is another matter.
To be honest this is the best news I've heard in a long time. There is light at the end of the tunnel.
Thanks Rivil,
I will take all the information I can get from here with me next week when I have an appointment with my consultant.
I will take all the information I can get from here with me next week when I have an appointment with my consultant.
Help me understand...
Genotype 3 SVR rates:
12 week treatment = 30 (19/64)
16 week treatment = 62* (39/63)
No cirrhosis
12 week treatment = 37 (14/38)
16 week treatment = 63 (25/40)
Cirrhosis
12 week treatment = 19 (5/26)
16 week treatment = 61 (14/23)
These are the % rates regarding those who have not achieved SVR. And moved on to the next step, as it would be. So if I am reading this right it means, breaking it down to the original group, lets say of 100, with 16 weeks in this treatment the SVR is 75% none cirrhosis.
Genotype 3 SVR rates:
12 week treatment = 30 (19/64)
16 week treatment = 62* (39/63)
No cirrhosis
12 week treatment = 37 (14/38)
16 week treatment = 63 (25/40)
Cirrhosis
12 week treatment = 19 (5/26)
16 week treatment = 61 (14/23)
These are the % rates regarding those who have not achieved SVR. And moved on to the next step, as it would be. So if I am reading this right it means, breaking it down to the original group, lets say of 100, with 16 weeks in this treatment the SVR is 75% none cirrhosis.
Sofosbuvir/Ribavirin will be on the market in 2014 and I remember reading that it had decent results for geno 3.
I will look for the link to the clinical studies and post it unless someone else gets to it first.
Hang in there, your chances of beating the virus are improving.
I will look for the link to the clinical studies and post it unless someone else gets to it first.
Hang in there, your chances of beating the virus are improving.
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
The data submitted in this NDA support the use of sofosbuvir and ribavirin (RBV) as an all-oral therapy for patients with genotype 2 and 3 HCV infection, and for sofosbuvir in combination with RBV and pegylated interferon (peg-IFN) for treatment-naïve patients with genotype 1, 4, 5 and 6 HCV infection.
----------------------------------------------------------------------------------------------
FUSION TRIAL - Genotype 2/3 treatment-experienced:
In the second study, known as the FUSION trial, patients who had not had a response to prior interferon therapy received sofosbuvir and ribavirin for 12 or 16 weeks.
The rates of sustained virologic response achieved with sofosbuvir and ribavirin in the population of patients with prior treatment were superior to the historical control rate of 25% (using peg-INF and RBV), with rates of 50% in the 12-week group and 73% in the 16-week group (P < .001).
The secondary analysis comparing rates of sustained virologic response between the groups showed that patients receiving 16 weeks of treatment had a significantly higher rate of sustained virologic response than patients receiving 12 weeks of treatment.
The most common adverse events were again headache, fatigue, nausea, and insomnia, but the overall discontinuation rate was low at 1% to 2%.
* Higher SVR12 rates higher in patients infected with genotype 2 vs genotype 3 HCV
* Higher SVR12 rates with 16-week therapy vs 12-week therapy in patients with genotype 3 HCV (62% vs 30%; P < .001), including in patients with or without cirrhosis
* Higher SVR12 rates with 16-week therapy vs 12-week therapy in cirrhotic patients infected with genotype 2 HCV
Genotype 3 SVR rates:
12 week treatment = 30 (19/64)
16 week treatment = 62* (39/63)
No cirrhosis
12 week treatment = 37 (14/38)
16 week treatment = 63 (25/40)
Cirrhosis
12 week treatment = 19 (5/26)
16 week treatment = 61 (14/23)
-------------------------------------------------------------------------------------------------
Hector